Literature DB >> 110693

Intramuscular and/or intralumbar postexposure treatment of rabies virus-infected cynomolgus monkeys with human interferon.

E Weinmann, M Majer, J Hilfenhaus.   

Abstract

From 9 to 10 of 10 cynomolgus monkeys infected with rabies street virus died of rabies about 20 days postinfection (pI). Symptoms of illness appeared 1 to 4 days before death. In an attempt to protect infected animals from the disease, human leukocyte interferon (HIF) was administered intramuscularly (i.m.) near the site of infection or into the cerebrospinal fluid between the first and second lumbar vertebrae (i.e., intralumbarly [i.l.]). Multiple HIF doses given over a period of several days proved more effective than a single HIF dose. In every experiment, i.m. HIF treatment was started 1 day pI. The best result obtained was a survival rate of 7 of 10 monkeys. The i.l. HIF administration schedules, consisting of multiple doses given over a period of at least 8 days, were started on day 3, 7, or 11 pI. Here the best result noted was the protection of 5 of 10 treated monkeys. The latest successful postexposure i.l. HIF treatment began on day 11 pI. The highest protection rate, 8 survivors of 10 treated monkeys, was achieved by a combined i.m. and i.l. HIF treatment. From these results we conclude that human patients severely bitten by rabid animals should in addition to an active immunization be i.m. and i.l. treated with HIF. Particularly, i.l. HIF administration could be effective, even when given several days pI. Whether an HIF administration starting after the appearance of clinical symptoms of rabies can help cannot be decided upon from the studies made in this monkey model. The most obvious difference between rabies in humans and cynomolgus monkeys is the duration of illness between the outbreak of the disease and death (1 to 4 days only in this animal model). It might have been due to this short period of illness that i.l. and i.m. HIF treatment at the appearance of clinical symptoms failed to help any of the monkeys treated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110693      PMCID: PMC414256          DOI: 10.1128/iai.24.1.24-31.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Interferon crosses blood-cerebrospinal fluid barrier in monkeys.

Authors:  D V Habif; R Lipton; K Cantell
Journal:  Proc Soc Exp Biol Med       Date:  1975-05

2.  Effect of administered human interferon on experimental rabies in monkeys.

Authors:  J Hilfenhaus; H E Karges; E Weinmann; R Barth
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

3.  Mechanism of the suppressive effect of interferon on antibody synthesis in vivo.

Authors:  B R Brodeur; T C Merigan
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

4.  Interferon-induced transfer of viral resistance between animal cells.

Authors:  J E Blalock; S Baron
Journal:  Nature       Date:  1977-09-29       Impact factor: 49.962

Review 5.  Interferons: anti-neoplastic drugs?

Authors:  H Strander
Journal:  Blut       Date:  1977-09-18

6.  Quantitative assay and potency test of antirabies serum and immunoglobulin.

Authors:  P Atanasiu
Journal:  Monogr Ser World Health Organ       Date:  1973

7.  Human leukocyte interferon for the treatment of herpes zoster in patients with cancer.

Authors:  T C Merigan; K H Rand; R B Pollard; P S Abdallah; G W Jordan; R P Fried
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

8.  Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine.

Authors:  G M Baer; J H Shaddock; S A Moore; P A Yager; S S Baron; H B Levy
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

9.  Administration of human interferon to rabies virus-infected monkeys after exposure.

Authors:  J Hilfenhaus; E Weinmann; M Majer; R Barth; O Jaeger
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

10.  Laboratory techniques in rabies: vaccine for man prepared in human diploid cells.

Authors:  H Koprowski
Journal:  Monogr Ser World Health Organ       Date:  1973
View more
  6 in total

1.  Exogenous interferon prolongs survival of rabies infected mice.

Authors:  S Mehta; S Roy; S Mukherjee; N Yadav; N Patel; A Chowdhary
Journal:  Virusdisease       Date:  2015-08-14

2.  Failure of interferon alfa and tribavirin in rabies encephalitis.

Authors:  M J Warrell; N J White; S Looareesuwan; R E Phillips; P Suntharasamai; P Chanthavanich; M Riganti; S P Fisher-Hoch; K G Nicholson; S Manatsathit
Journal:  BMJ       Date:  1989-09-30

3.  λ-Carrageenan P32 Is a Potent Inhibitor of Rabies Virus Infection.

Authors:  Zhaochen Luo; Dayong Tian; Ming Zhou; Wenjie Xiao; Yachun Zhang; Mingming Li; Baokun Sui; Wei Wang; Huashi Guan; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

Review 4.  The need for new antiviral agents.

Authors:  D S Freestone
Journal:  Antiviral Res       Date:  1985-12       Impact factor: 5.970

5.  Glu333 in rabies virus glycoprotein is involved in virus attenuation through astrocyte infection and interferon responses.

Authors:  Yukari Itakura; Koshiro Tabata; Kohei Morimoto; Naoto Ito; Herman M Chambaro; Ryota Eguchi; Ken-Ichi Otsuguro; William W Hall; Yasuko Orba; Hirofumi Sawa; Michihito Sasaki
Journal:  iScience       Date:  2022-03-22

Review 6.  Macaque models of human infectious disease.

Authors:  Murray B Gardner; Paul A Luciw
Journal:  ILAR J       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.